MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

20.32 -3.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.17

Max

20.51

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.633

89.037

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-11.85% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

279M

1.1B

Vorige openingsprijs

23.33

Vorige sluitingsprijs

20.32

Nieuwssentiment

By Acuity

50%

50%

142 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jan 2026, 18:41 UTC

Winsten

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24 jan 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

24 jan 2026, 06:18 UTC

Acquisities, Fusies, Overnames

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 jan 2026, 22:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 jan 2026, 22:30 UTC

Marktinformatie

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 jan 2026, 22:03 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 21:52 UTC

Winsten
Acquisities, Fusies, Overnames

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

23 jan 2026, 21:39 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 jan 2026, 21:12 UTC

Winsten

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 jan 2026, 20:31 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 20:12 UTC

Marktinformatie

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 jan 2026, 20:07 UTC

Marktinformatie

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 jan 2026, 19:36 UTC

Marktinformatie

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 jan 2026, 19:30 UTC

Marktinformatie
Winsten

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 jan 2026, 19:18 UTC

Marktinformatie

Gold and Silver Step Up to More Records -- Market Talk

23 jan 2026, 19:15 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23 jan 2026, 18:53 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23 jan 2026, 18:21 UTC

Winsten

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23 jan 2026, 18:19 UTC

Marktinformatie

Intel Seen as Increasingly Confident on Demand -- Market Talk

23 jan 2026, 17:59 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23 jan 2026, 17:57 UTC

Marktinformatie

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23 jan 2026, 17:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-11.85% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -11.85%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

142 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat